Drugs in Dev. Rheumatology
Phase IV
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The co-administration of KRYSTEXXA (pegloticase) with an immunomodulator like methotrexate has increasingly been employed in patients with uncontrolled gout to help reduce the development of antidrug antibodies, which can affect treatment efficacy with b...
Product Name : Krystexxa
Product Type : Large molecule
Upfront Cash : Not Applicable
November 08, 2022
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The MIRROR randomized controlled trial outcomes provided a clear view of improvements in patient response and reductions in infusion reactions for KRYSTEXXA plus low-dose (15 mg/week) methotrexate compared to KRYSTEXXA plus placebo.
Product Name : Krystexxa
Product Type : Large molecule
Upfront Cash : Not Applicable
June 01, 2022
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KRYSTEXXA® (pegloticase injection) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.
Product Name : Krystexxa
Product Type : Large molecule
Upfront Cash : Not Applicable
May 24, 2022
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Application based on recent MIRROR randomized controlled trial results, which showed 71% of patients randomized to receive KRYSTEXXA (pegloticase), a PEGylated uric acid specific enzyme plus methotrexate achieved a complete response.
Product Name : Krystexxa
Product Type : Large molecule
Upfront Cash : Not Applicable
March 07, 2022
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : sBLA Submission based on recent results from the MIRROR randomized clinical trial, which showed a 71% response rate for patients randomized to receive KRYSTEXXA (Pegloticase) PEGylated uric acid specific enzyme, plus methotrexate for people living with u...
Product Name : Krystexxa
Product Type : Large molecule
Upfront Cash : Not Applicable
January 10, 2022
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Rheumatology
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Reset All
